“…Of the five types of S1P receptor, type 1 S1P receptors (S1P1) are expressed preferentially by lymphocytes, and determine lymphocyte emigration from and retention in the lymphoid tissues [16,17]. Accumulating evidence has revealed the pivotal role of S1P in the development of inflammatory diseases such as autoimmune type 1 diabetes, rheumatoid arthritis and multiple sclerosis [16,18]. It was reported recently that FTY720, a non-selective S1P receptor agonist, ameliorated intestinal inflammation in several murine colitis models [IL-10 -/-mice [19], trinitrobenzene sulphonic acid (TNBS)-induced colitis [20], dextran sulphate sodium (DSS)-induced and CD4…”